Additional value of hybrid SPECT/CT systems in neuroendocrine tumors, adrenal tumors, pheochromocytomas and paragangliomas

Binary Particle Swarm Optimization Intelligent Feature Optimization Algorithm-Based Magnetic Resonance Image in the Diagnosis of Adrenal Tumor

This research was aimed to explore the application value of magnetic resonance imaging (MRI) based on binary particle swarm optimization algorithm (BPSO) in the diagnosis of adrenal tumors. 120 patients with adrenal tumors admitted to the hospital were selected and randomly divided into the control group (conventional MRI examination) and the observation group (MRI examination based on the BPSO intelligent feature optimization algorithm), with 60 cases in each group. The sensitivity, specificity, accuracy, and Kappa of the diagnostic methods were compared between the two groups. The results showed that the calculation rate of the BPSO algorithm was the best under the same processing effect (P < 0.05). Optimization algorithm-based MRI is used in the diagnosis of adrenal tumors, and the results showed that the sensitivity, specificity, accuracy, and Kappa (83.33%, 79.17%, 81.67%, and 0.69) of the observation group were higher than those of the control group (50%, 75%, 58.33%, and 0.45). The similarity of tumor location results in the observation group (89.24%) was significantly higher than that in the control group (65.9%) (P < 0.05). In conclusion, compared with SFFS and other algorithms, the BPSO algorithm has more advantages in calculation speed. MRI based on the BPSO intelligent feature optimization algorithm has a good diagnostic effect and higher accuracy in adrenal tumors, showing the good development prospects of computer intelligence technology in the field of medicine.

MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies

Metaiodobenzylguanidine, a guanithidine analog, labeled with ¹²³I and ¹³¹I, is used for imaging and therapy of neuroblastomas and various neural crest tumors like paragangliomas, pheochromocytomas, medullary cancer of thyroid and carcinoids since the past three to four decades. In this review article, we shall revisit metaiodobenzylguanidine as a radiopharmaceutical and its various applications in neural crest tumors.